Copyright
©The Author(s) 2025.
World J Gastrointest Pharmacol Ther. Jun 5, 2025; 16(2): 101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Published online Jun 5, 2025. doi: 10.4292/wjgpt.v16.i2.101268
Figure 2 Proportions of patients meeting study endpoint active agent vs placebo.
A: Entire group; B: Patients with Crohn’s disease; C: Patients with ulcerative colitis.
- Citation: Fennessy A, Doyle M, Boland A, Bourke R, O'Connor A. Four-strain probiotic exerts a positive effect on irritable bowel syndrome symptoms occurring in inflammatory bowel diseases in absence of inflammation (train-IBD trial). World J Gastrointest Pharmacol Ther 2025; 16(2): 101268
- URL: https://www.wjgnet.com/2150-5349/full/v16/i2/101268.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v16.i2.101268